Progressive supranuclear palsy (PSP), previously believed to be a common cause of
atypical parkinsonism, is now recognised as a range of motor and behavioural syndromes …

Multiple-system atrophy is a neurodegenerative disease characterized by progressive
autonomic failure, parkinsonism, and cerebellar and pyramidal tract symptoms. Glial …

A randomized, double-blind, placebo-controlled, 52-week study (no. NCT03068468)
evaluated gosuranemab, an anti-tau monoclonal antibody, in the treatment of progressive …

Parkinson’s Disease and Its Management - PMC Back to Top Skip to main content NIH NLM
Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search …

Objectives: To estimate the lifetime risk, prevalence, incidence, and mortality of the principal
clinical syndromes associated with frontotemporal lobar degeneration (FTLD) using revised …

Background Progressive supranuclear palsy is a neurodegenerative disorder associated
with tau protein aggregation. Tilavonemab (ABBV-8E12) is a monoclonal antibody that binds …

Tauopathies are classified according to whether tau deposits predominantly contain tau
isoforms with three or four repeats of the microtubule-binding domain. Those in which four …

Background Multiple system atrophy (MSA) is a fatal and still poorly understood
degenerative movement disorder that is characterised by autonomic failure, cerebellar …

The phenotypic variability of progressive supranuclear palsy (PSP) may account for its
frequent misdiagnosis, in particular in early stages of the disease. However, large …

Background Multiple system atrophy is a rare, fatal neurodegenerative disorder with
symptoms of autonomic failure plus parkinsonism, cerebellar ataxia, or both. We report …